Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2714-2724

  Sweeney, Paul ^a   Karashima, Takashi ^a   Kim, Sun Jin ^a   Kedar, Daniel ^a   Mian, Badar ^a   Huang, Samuel ^a   Baker, Cheryl ^a   Fan, Zhen ^a   Hicklin, Daniel J ^a   Pettaway, Curtis A ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; GELATINASE B; MONOCLONAL ANTIBODY DC101; PACLITAXEL; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY; ANTIBODY; MESSENGER RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENZYME SYNTHESIS; EVALUATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TIBIA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CYTOLOGY; ENDOTHELIUM; IMMUNOLOGY; METABOLISM; METASTASIS; NUCLEIC ACID HYBRIDIZATION; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TIME;

ANIMAL; ANTIBODIES; APOPTOSIS; CELL DIVISION; ENDOTHELIUM; GELATINASE B; HUMAN; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NUCLEIC ACID HYBRIDIZATION; PROSTATIC NEOPLASMS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ANIMALS; HUMANS; MATRIX METALLOPROTEINASE 9;

EID: 0036023438     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cancer Statistics 2001
2. Tumor angiogenesis: Therapeutic implications
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Vascular endothelial growth factor (VEGF) and its receptors
5. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
6. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop
7. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor
8. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
9. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
10. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
11. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
12. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
13. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
14. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
15. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
16. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis
17. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
18. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice
19. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
20. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
21. Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice
22. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas
23. Complete one-hour immunocytochemistry based on capillary action
24. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdrl in mouse colon carcinoma cells
25. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
26. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
27. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
28. Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells
29. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma
30. Highly metastatic human prostate cancer growing within the prostate of athymic mice over-expresses vascular endothelial growth factor
31. Angiogenesis and prostate cancer: Identification of a molecular progression switch
32. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study
33. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
34. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer
35. A Relative expression of type IV collagenase. E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organconfined from pathologically advanced prostate cancers
36. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma
37. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer
38. Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors
39. Interstitial collagenase is required for angiogenesis in vitro
40. MMP-9/ gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
41. r 72, 000) expression in human prostate: Benign and malignant tissue
42. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia
43. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma
44. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer
45. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
46. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
47. Clinical studies of angiogenesis inhibitors: The University of Texas MD Anderson Center Trial of Human Endostatin